Navigation Links
Burke would like to double Act 255 angel tax credits

State commerce secretary Mary Burke said this week that she would like Wisconsin to double the amount of tax credits available to angel investors under the Act 255 program.

In an interview, Burke said funding increases would be contingent on the state's fiscal health, but she would like to double the tax credits from the $3 million allocated in the current biennial budget. Under Act 255, ......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 03/30/06


Page: 1 2

Related biology technology :

1. Commerce secretary Mary Burke on innovation, expansion and BIO
2. GenTel Appoints Burke to its Scientific Advisory Board
3. Federal bill would set healthcare IT standards
4. Bill would provide federal aid for healthcare IT
5. Proposed telecom bill would have Katrina impact
6. Reader predictions would make 2007 quite a year
7. Bill would ban computers from landfills
8. Bill would deny tax credits to firms creating stem-cell cultures
9. Bill would require data keepers to notify consumers of info leaks
10. Innovation prize-winner would help firefighters get out alive
11. Madison asks for wireless bids; airport, downtown would be first
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Burke would like double Act angel tax credits

Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6